



SUGGESTED FORMULA

Azelaic Acid 12.5% / Finasteride 0.1% / Minoxidil 5% / Ketoconazole 2% Solution

Version number: 1.0

Volume: 100mL

Azelaic Acid	12.5gm
Finasteride, USP (F1300)	0.1gm
Minoxidil, USP (M1138)	5gm
Ketoconazole, USP (K1149)	2gm
Alcohol 95%, USP (ET108)	70mL
Hydrochloric Acid 10% (w/v) (HY105)	q.s. for pH
Sodium Hydroxide (10% - prepared from Pellets, NF)	q.s. for pH
Purified Water, USP (W1014)	Q.S. 100mL

Wear appropriate personal protective equipment.

This compound should be prepared in a USP Chapter <800> compliant containment primary engineering control (C-PEC).

SUGGESTED COMPOUNDING PROCEDURES

1. Accurately weigh and/or measure each ingredient
2. In a calibrated vessel add Azelaic Acid, Finasteride, Minoxidil, Ketoconazole and Alcohol 95% and let spin
3. Add Purified water to approximately 90% (90mL)
4. Slowly add Hydrochloric acid and observe for dissolution of powder as preparation is mixing on stir plate
5. Allow to mix on stir plate and continue adding HCl until dissolution is complete, check pH and adjust with either Hydrochloric acid or Sodium Hydroxide to pH 6.0 to 6.5
6. Bring solution to final volume with Purified Water and spin to mix
7. Package in light resistant, glass containers and label
8. Suggested quality assessments:
 - a. Clarity
 - b. Color
 - c. Label (s)- auxiliary labels (external use), storage, BUD

Protect from light.

Store in amber glass bottle

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned according to the current USP Chapter <795>

Precautions:

Hazardous drugs should be handled according to USP, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a vertical airflow hood, in a biological safety cabinet or barrier isolation technology. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.

7/19 JD